Home > Oncology > Accurate prediction of bladder-cancer response to neoadjuvant chemotherapy remains elusive

Accurate prediction of bladder-cancer response to neoadjuvant chemotherapy remains elusive


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
European Urology
Reuters Health - 10/09/2020 - Clinical restaging and tumor sequencing do not accurately indicate the response of muscle-invasive bladder cancer (MIBC) to neoadjuvant chemotherapy (NAC), according to a database study. Many institutions undertake restaging evaluations after NAC and prior to consolidation therapy with radical cystectomy in patients with MIBC. Whether such evaluations accurately reflect individual patient responses to NAC remains unclear. Dr. Russell E. N. Becker of Johns Hopkins Medicine, in Baltimore, Maryland, and colleagues evaluated the accuracy of endoscopic visual and tissue restaging after NAC and explored the prognostic value of tumor mutation analysis as an adjunct to post-NAC restaging protocols in their study of 114 patients with MIBC who underwent NAC followed by radical cystectomy. The presence of residual MIBC on restaging transurethral resection (TUR) was only 27% sensitive (but 95% specific) for predicting residual MIBC at radica...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on